|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2011-1-7
|
|
pubmed:abstractText |
Despite its proven efficacy, infliximab is often considered to be an expensive treatment for patients with psoriatic arthritis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor,
http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/adalimumab,
http://linkedlifedata.com/resource/pubmed/chemical/infliximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1524-4733
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
15-23
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:21211482-Antibodies, Monoclonal,
pubmed-meshheading:21211482-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:21211482-Antirheumatic Agents,
pubmed-meshheading:21211482-Arthritis, Psoriatic,
pubmed-meshheading:21211482-Cost-Benefit Analysis,
pubmed-meshheading:21211482-Decision Support Techniques,
pubmed-meshheading:21211482-Disease Progression,
pubmed-meshheading:21211482-Female,
pubmed-meshheading:21211482-Great Britain,
pubmed-meshheading:21211482-Health Care Costs,
pubmed-meshheading:21211482-Humans,
pubmed-meshheading:21211482-Immunoglobulin G,
pubmed-meshheading:21211482-Male,
pubmed-meshheading:21211482-Middle Aged,
pubmed-meshheading:21211482-Models, Econometric,
pubmed-meshheading:21211482-Palliative Care,
pubmed-meshheading:21211482-Quality-Adjusted Life Years,
pubmed-meshheading:21211482-Receptors, Tumor Necrosis Factor,
pubmed-meshheading:21211482-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis.
|
|
pubmed:affiliation |
McMaster Development Consultants Ltd., Glasgow, Scotland, UK.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|
